Fox Chase | Strategic Alliance Partners

Latest from Fox Chase


Radiation Strategies Blaze a Trail for Better Outcomes in CNS Cancers and Beyond

May 21, 2021

Stephanie E. Weiss, MD, FASTRO and Eric M. Horwitz, MD, FABS, FASTRO, discuss ways to leverage radiation in the treatment of central nervous system metastases, areas of active investigation, and different available strategies that are improving outcomes for patients with cancer.

Ibrutinib Plus Venetoclax Results in High Residual Disease Eradication in CLL Model

May 17, 2021

The combination of ibrutinib and venetoclax were found to act on distinct subpopulations of chronic lymphocytic leukemia that have different proliferative capacities in an ex vivo model of the disease, suggesting that the dual-targeted approach has the potential to eradicate residual disease in patients with CLL.

Immunotherapy Makes Waves in Gastroesophageal and Gastric Cancers

March 24, 2021

Namrata (Neena) Vijayvergia, MD, discusses the emerging role of immunotherapy in resectable and metastatic esophageal and gastric cancers, as well as key nuances that could complicate these agents’ utility in clinical practice.

NCCN Guidelines for Gastric and Esophageal Cancers Updates Encompass Immunotherapy, TKIs Across Settings

March 20, 2021

Key updates to the National Comprehensive Cancer Network guidelines for gastric and esophageal cancers include the incorporation of immune checkpoint inhibitors spanning settings in patients with gastroesophageal cancer, the inclusion of fam-trastuzumab deruxtecan-nxki for those with HER2-positive gastric cancer, and the addition of recommended ramucirumab combinations for use in second- or later-line settings.